Legend Biotechnology

Carvykti (ciltacabtagene autoleucel) is a BCMA CAR-T for relapsed/refractory multiple myeloma, advanced through the LEGEND-2 programme and a growing real-world evidence base.

Country: China
Ticker: LEGN

Commercial BCMA CAR-T (Carvykti co-originator)

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Revenue	$1.9 billion in FY 2025 net trade sales for CARVYKTI; $597 million in Q1 2026 net trade sales for CARVYKTI	investors.legendbiotech.com · legendbiotech.gcs-web.com · sec.gov
Headcount	Approximately 6,316 employees as of March 2026	investors.legendbiotech.com · legendbiotech.gcs-web.com
Production site	Raritan, NJ (US); Obelisc and Tech Lane in Ghent, Belgium (EU); Morris Plains, NJ (CMO)	investors.legendbiotech.com · sec.gov
Capacity	Installed capacity to support treatment of up to 10,000 patients annually at the expanded Raritan facility as of 2026	investors.legendbiotech.com · legendbiotech.gcs-web.com · sec.gov
Regulatory approval	CARVYKTI is approved for relapsed/refractory multiple myeloma in the US, Europe, Japan, Brazil, Canada, and China (4L+)	investors.legendbiotech.com · legendbiotech.gcs-web.com · myeloma.org
Funding	$350 million upfront payment from Janssen for worldwide license (2017); $423.8 million in gross proceeds from Nasdaq listing (2020)	sec.gov · thepharmaletter.com

Independent sources: investors.legendbiotech.com · myeloma.org · sec.gov · thepharmaletter.com

Technologies

Name	Cluster	Risk
CAR-T cell therapy	therapeutics-platforms	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.